Oxyntomodulin
Also called OXM, Glucagon(1-37)
Subcutaneous (under the skin)Human study reference
Research reference
Human study
Oxyntomodulin four-week randomized study
Three injections daily, 30 minutes before meals
4 weeks
Wynne et al., Diabetes (2005) ↗When results may show
- When change was measured
- Weight and food intake were compared at the start and end of four weeks.
- When to assess
- 4 weeks
- Conditions and limitations
- Overweight and obese volunteers. This is a short experimental meal-linked schedule, not proof of long-term safety or a fixed every-eight-hours plan. The amount is not reconstructed from secondary summaries.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: Wynne et al., Diabetes (2005)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Oxyntomodulin describe 1–2 mg per administration. Descriptive only, not a recommendation.
Modelled level — twice a day
1× is the peak after a single dose.
- Steady-state peak
- 0.98× single dose
- Time to steady state
- 1hours
- Administrations
- 14/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Wynne et al., Diabetes (2005)This is a short experimental meal-linked schedule, not proof of long-term safety or a fixed every-eight-hours plan. The amount is not reconstructed from secondary summaries.
Next steps
Oxyntomodulin beginner guideOpen Oxyntomodulin planning worksheetEstimate Oxyntomodulin vial costTrack Oxyntomodulin notes